StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
0222.KL$0.53+0.95%
Fair $0.53+0.0%

0222.KL

Optimax Holdings Berhad

Healthcare / Medical Care FacilitiesKuala Lumpur

$0.53

+0.00 (+0.95%)

Fairly Valued+0.0%Fair Value $0.53Fund rank 33/100 · Data gapFallback financials|
SA 43/C
F-Score: 6/9
Margin Compression

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $13.5M · quality 62.3/100

Data gap 33/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 53/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

43/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. Operating margin has declined for 3 consecutive years
Thesis & Journal · 0222.KLLocal privado en este navegador · Optimax Holdings Berhad
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$288M

P/E

26.5x

↑

EV/EBITDA

8.0x

↓

ROE

18.9%

↑

Gross Margin

78.3%

↑

Debt/Equity

0.67

↑
52-Week Range$1
$0$1

TradingView lightweight chart

0222.KL price, volumen y niveles de valoración

Último $0.530Periodo +54.7%
Fair value: $0.530

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+7.9%

FCF CAGR

+18.0%

FCF margin

19.3%

FCF / Net income

1.88x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $135.7M · net income $13.9M · FCF $26.2M

2022-FY → 2025-FY

Gross margin

78.3%+0.2% pts

Operating margin

16.9%-5.9% pts

Net margin

10.3%-3.3% pts

FCF margin

19.3%+4.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$135.7M$135.7M$127.7M$114.0M$108.0M
Net Income$13.9M$13.9M$13.0M$12.9M$14.7M
EBITDA$39.6M$39.6M$37.1M$31.3M$32.6M
EPS——0.020.020.03
Gross Margin78.3%78.3%79.5%78.4%78.1%
Operating Margin16.9%16.9%17.6%18.6%22.8%
Net Margin10.3%10.3%10.2%11.3%13.6%
Balance Sheet
Debt/Equity0.670.670.870.530.45
Current Ratio1.581.58———
Cash Flow
Free Cash Flow$26.2M$26.2M$-2.1M$13.5M$15.9M
Returns
ROE18.9%18.9%19.2%20.5%25.3%
Valuation
P/E26.5026.5025.9726.9629.03
EV/EBITDA8.018.0110.2011.6513.34
P/B3.903.904.985.527.34
Growth & Yield
Revenue Growth6.3%6.3%12.1%5.5%—
EPS Growth——0.4%-13.9%—
Dividend Yield2.6%2.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +4.6%

Total return

+4.6%

Start / end P/E

n/dx → n/dx

EPS bridge

0.02 → n/d

Residual

+1.9%

EPS growthn/d
Multiple reratingn/d
Dividend+2.6%
Residual / FX / buybacks / cross-term+1.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.